Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report

Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report

Histologic transformation is one of the mechanisms of resistance to EGFR tyrosine kinase inhibitor in patients with NSCLC with EGFR mutation. The transformation from adenocarcinoma to squamous cell carcinoma (SCC) has been recently recognized as a mechanism of resistance to osimertinib. The prognosi...

Full description

Bibliographic Details
Main Authors: Shota Takahashi, MD, Yuki Sato, MD, Yoshiharu Sato, PhD, Ryosuke Hirabayashi, MD, Shigeo Hara, MD, PhD, Yutaka Takahashi, MD, PhD, Keisuke Tomii, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:JTO Clinical and Research Reports
Subjects:
Acquired resistance
Histologic transformation
Osimertinib
Immune checkpoint inhibitor
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000092

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324000092

Similar Items